ÐÂÎÅÖÐÐÄ
News Center
È«Çò40%θ°©ÔÚÖйú £¬ £¬ÖйúÉúÎïÖÆÒ©Á¢Òì°Ðµã¡°È«¸±Îä×°¡±£¡ £¡£¡
Ðû²¼Ê±¼ä£º2025-04-09
½ñÌìÊǵÚ20¸ö“¹ú¼Ê»¤Î¸ÈÕ”¡£¡ £¡£¡£×÷ΪÈËÌåÓªÑøµÄ“¼Ó¹¤³§” £¬ £¬´ÓÂýÐÔθÑס¢¡¢¡¢Î¸À£Ññµ½ÖÂÃüθ°© £¬ £¬Î¸µÄ“¿µ½¡¾¯ÖÓ”ÒÑÈ»ÇÃÏì¡£¡ £¡£¡£ÖйúÉú³ÝԼռȫÇò×ÜÉú³ÝµÄ18% £¬ £¬µ«Î¸°©µÄ·¢²¡ÂÊԼռȫÇòµÄ40% £¬ £¬ÇÒÄêÇáÈË»¼Î¸°©µÄ±ÈÂÊÔ½À´Ô½¸ß[1,2]¡£¡ £¡£¡£½üÄêÀ´ £¬ £¬Ëæ×Å°ÐÏòÖÎÁƺÍÃâÒßÖÎÁƵĿìËÙÍƽø £¬ £¬Ðí¶àÐÂÐÍÒ©ÎïµÄ»ñÅúºÍÐÂÖÎÁÆģʽµÄ³ÉÊì £¬ £¬Ê¹µÃθ°©µÄÁÙ´²ÖÎÁÆÊÖ¶ÎÈÕÒ渻ºñ¡£¡ £¡£¡£ÔÚÕⳡθµÄ“ÊØÎÀÕ½”ÉÏ £¬ £¬ÖйúÉúÎïÖÆÒ©£¨1177.HK£©Á¢Òì°ÐµãÒÑÈ«¸±Îä×°£¡ £¡£¡
θ°©ÒþÄäÐÔÇ¿¡¢¡¢¡¢ÄÑÒÔ¼ì²â £¬ £¬µ¼Ö·¢²¡ÂʸßÇÒÔ¤ºó²»Á¼¡£¡ £¡£¡£ÏµÍ³ÐÔ»¯ÁÆ¡¢¡¢¡¢·ÅÁƺÍÊÖÊõÇгýµÈ¹Å°åÖÎÁÆÒªÁìÁÆЧÓÐÏÞ £¬ £¬µ¼ÖÂÍíÆÚθ°©»¼ÕßµÄ5ÄêÉúÑÄÂʼ«µÍ[3,4]¡£¡ £¡£¡£°ÐÏòÖÎÁƺÍÃâÒßÖÎÁƳÉΪº£ÄÚÍâθ°©ÁìÓòµÄÑо¿ÈÈÃÅ £¬ £¬ÒÔHER2¡¢¡¢¡¢VEGF¡¢¡¢¡¢Claudin18.2Ϊ°ÐµãµÄ°ÐÏòÒ©ÎïÔÚÁÙ´²ÉÏÒѾÓÐÖî¶àЧ¹û£»£»£»PD-1µ¥¿¹ÁªºÏ»¯ÁÆÒѳÉΪ²»¿ÉÇгý¾Ö²¿ÍíÆÚ»òתÒÆÐÔʳ¹ÜθÁ¬Ïµ²¿/θ°©»¼ÕßµÄÒ»ÏßÖÎÁÆбê×¼[5]¡£¡ £¡£¡£¾Û½¹ÍíÆÚθ°©°ÐÏòÖÎÁÆ £¬ £¬ÊÂʵÓÐÄÄЩÒѾÉÏÊлòÕýÔÚ¿ª·¢µÄÈÈÃŰеãÄØ£¿£¿
¿¹HER2ÖÎÁÆ£º12%θ°©»¼ÕߵēÉúÑÄÃÜÂë”
ÈËÀà±íƤÉú³¤Òò×ÓÊÜÌå2£¨HER2£©ÊÇÏÖÔÚθ°©ÖÐÃ÷È·µÄÖÎÁưе㠣¬ £¬HER2¹ý±í´ï»áÈÃÖ×Áö³¤µÃ¸ü¿ì¡¢¡¢¡¢¸üÈÝÒ×תÒÆ £¬ £¬Öйú¹æÄ£ÄÚθ°©»¼ÕßHER2ÑôÐԵıÈÀýԼΪ12%¡£¡ £¡£¡£ÇúÍ×Öéµ¥¿¹ÊÇÒ»ÖÖÕë¶Ô HER2°ûÍâ½á¹¹ÓòµÄÖØ×éÈËÔ´»¯IgG1µ¥¿Ë¡¿¹Ìå £¬ £¬ÆäÁªºÏ»¯ÁÆÊÇÏÖÔÚθ°©Ò»ÏßÖÎÁƵÄÖ÷ÒªÕ½ÂÔ¡£¡ £¡£¡£ÇúÍ×Öéµ¥¿¹Äܹ»¸ßÇ׺ÍÁ¦Á¬Ïµ²¢×è¶ÏHER2½éµ¼µÄϸ°ûÐźÅͨ· £¬ £¬ÃæÁÙHER2¹ý±í´ïµÄÖ×Áöϸ°û £¬ £¬Í¨¹ý¿¹ÌåÒÀÀµµÄϸ°û½éµ¼¶¾ÐÔ×÷Óã¨ADCC£©¶ÔÆäÔì³ÉɱÉË¡£¡ £¡£¡£2023Äê7Ô £¬ £¬ÖйúÉúÎïÖÆÒ©ÏÂÊôÆóÒµÕý´óÌìÇçÑб¬·¢²úµÄ×¢ÉäÓÃÇúÍ×Öéµ¥¿¹£¨É̱êÃû£ºÈüÍ×£©»ñÅúÉÏÊÐ £¬ £¬ÓÃÓÚHER2ÑôÐÔÔçÆÚÈéÏÙ°©¡¢¡¢¡¢×ªÒÆÐÔÈéÏÙ°©¼°×ªÒÆÐÔθ°©µÄÖÎÁÆ¡£¡ £¡£¡£
¿¹VEGFÖÎÁÆ£ºÇжÏÖ×ÁöµÄ“ÉúÃü²¹¸øÏß”
Ѫ¹ÜÌìÉú¶Ô°©Ö¢µÄÉú³¤ºÍתÒÆÖÁ¹ØÖ÷Òª £¬ £¬Òò´ËÒÖÖÆѪ¹ÜÌìÉúÔÚθ°©ÖÐÊܵ½ÁËÆÕ±éµØ¹Ø×¢¡£¡ £¡£¡£Ñª¹ÜÄÚƤÉú³¤Òò×Ó£¨VEGF£©Í¨¹ýÔö½øÄÚƤϸ°ûÔöÖ³ºÍÔöÌíѪ¹Üͨ͸ÐÔÀ´ÓÕµ¼Ö×ÁöѪ¹ÜÌìÉú[6]¡£¡ £¡£¡£Î¸°©×é֯ͨ³£¸ß±í´ïVEGF £¬ £¬²¢Óë¸üÍíÆڵļ²²¡ºÍ½Ï²îµÄÔ¤ºóÏà¹Ø¡£¡ £¡£¡£±´·¥Öéµ¥¿¹×÷ΪһÖÖÒÔVEGFΪ°ÐµãµÄÖØ×éÈËÔ´»¯IgG1µ¥¿Ë¡¿¹Ìå £¬ £¬Äܹ»ÓëVEGFµÄÒÖÖÆÊÜÌåÁ¬Ïµ £¬ £¬²¢Ê¹ÓÿØÖÆѪ¹ÜÉú³¤Àú³ÌÖÐËùÐèÒªµÄÑõÆø¡¢¡¢¡¢ÓªÑø £¬ £¬µÖ´ï×èÖ¹Ö×Áöϸ°ûÉú³¤ºÍתÒƵÄÄ¿µÄ[7]¡£¡ £¡£¡£2023Äê3Ô £¬ £¬Õý´óÌìÇçÑб¬·¢²úµÄ±´·¥Öéµ¥¿¹×¢ÉäÒº£¨É̱êÃû£º°²±¶Ë¹£©»ñÅúÉÏÊÐ £¬ £¬ÒÑ»ñÅú˳Ӧ֢º¸ÇתÒÆÐÔ½áÖ±³¦°©¡¢¡¢¡¢¸´·¢ÐÔ½ºÖÊĸϸ°ûÁö¡¢¡¢¡¢ÉÏƤÐÔÂѳ²°©¡¢¡¢¡¢ÊäÂѹܰ©»òÔ·¢ÐÔ¸¹Ä¤°©¡¢¡¢¡¢¹¬¾±°©¡¢¡¢¡¢¸Îϸ°û°©ÒÔ¼°ÍíÆÚ¡¢¡¢¡¢×ªÒÆÐÔ»ò¸´·¢ÐÔ·ÇСϸ°û·Î°©¡£¡ £¡£¡£
¿¹Claudin18.2ÖÎÁÆ£ºÖØ°õ°ÐµãÐý·çÀ´Ï®
ClaudinÂÑ°×ÊÇϸ°û¼äϸÃÜÅþÁ¬µÄÖ÷Òª½á¹¹ÂÑ°× £¬ £¬ÆäÑÇÐÍClaudin18.2ÌØÒìÐÔ±í´ïÓÚ·Ö»¯µÄθÉÏƤϸ°û £¬ £¬²¢ÔÚϸ°û¶ñ±äÀú³ÌÖб»Ì«¹ý¼¤»î £¬ £¬ÔÚÒÈÏÙ°©¡¢¡¢¡¢Ê³¹Ü°©ºÍ½áÖ±³¦°©ÖÐÒ²Óбí´ï¡£¡ £¡£¡£ÏÖÓÐÑо¿Åú×¢ £¬ £¬Claudin18.2ÔÚθ°©ÖеÄÑôÐÔÂÊԼΪ16%-73%[8],Ïà±ÈÓÚHER2ÔÚθ°©ÖеÄÑôÐÔÍ»±äÂÊÏÔ×Å½Ï¸ß £¬ £¬Òò´ËClaudin18.2°ÐÏòÒ©Îï¿ÉÒÔʹ¸ü¶à»¼Õß»ñÒæ¡£¡ £¡£¡£TQB2103ÊÇÕý´óÌìÇçÑз¢µÄÒ»¿î°ÐÏòClaudin18.2µÄ¿¹ÌåżÁªÒ©Îï(ADC) £¬ £¬ÏÖÔÚÕýÔÚÕë¶ÔÍíÆÚ¶ñÐÔÖ×Áö¿ªÕ¹ÁÙ´²ÊÔÑé¡£¡ £¡£¡£³ýÁËθ°© £¬ £¬Claudin18.2ÔÚÒÈÏÙ°©¡¢¡¢¡¢Ê³¹Ü°©ºÍ·Î°©µÈ·¢Ã÷¸ß±í´ï £¬ £¬ÕâʹµÃClaudin18.2Ò²³ÉΪDZÁ¦ÖØ´óµÄÖÎÁưе㡣¡ £¡£¡£
δÀ´Õ½³¡£¡ £¡£¡£º¸öÐÔ»¯ÖÎÁƼ°ÄÍÒ©»úÖÆÍ»ÆÆ
¾Û½¹°ÐÏòÖÎÁÆ £¬ £¬Õý´óÌìÇç×ÔÖ÷Ñз¢µÄ1ÀàÁ¢ÒìÒ©TQB2210ÓÚ¿ËÈÕ»ñÅúÁÙ´² £¬ £¬Ê׸ö˳Ӧ֢ÄâÓÃÓÚÖÎÁÆÍíÆÚ¶ñÐÔÖ×Áö¡£¡ £¡£¡£TQB2210ÊÇÒ»¿î°ÐÏòFGFR2bµÄÈËÔ´»¯µ¥¿Ë¡¿¹Ìå £¬ £¬FGFR2bµÄ¹ý±í´ïÓëθ°©¡¢¡¢¡¢ÈéÏÙ°©¡¢¡¢¡¢¸ÎÄÚµ¨¹Ü°©µÈ¸ßÇÖÏ®ÐÔÖ×ÁöÇ×½üÏà¹Ø £¬ £¬Ô¼30%µÄHER2ÒõÐÔÍíÆÚθ°©»¼ÕßÖб£´æFGFR2b¹ý±í´ï[9]¡£¡ £¡£¡£ÏÖÔÚÈ«Çò¹æÄ£ÄÚÉÐδÓÐͬ°ÐµãÒ©ÎïÉÏÊÐ £¬ £¬¿ª·¢°ÐÏòFGFR2bµÄÖÎÁÆ·½°¸ £¬ £¬½«ÓÐÖúÓÚÍƽøθ°©¾«×¼ÖÎÁÆ¡£¡ £¡£¡£
ÐÂÐÍÖÎÁÆÒªÁìµÄÑз¢ºÍÓ¦Óñض¨ÒªÃæÁÙÖî¶àÌôÕ½¡£¡ £¡£¡£ÔõÑù̽Ë÷³öÔ½·¢ÓÐÓᢡ¢¡¢Çå¾²µÄÖÎÁÆÒªÁì £¬ £¬ÔõÑùʵÏÖ¸öÐÔ»¯ÖÎÁÆ £¬ £¬ÒÔ¼°ÔõÑùÉîÈëÏàʶҩÎïÄÍÒ©»úÖƵÈÎÊÌâÓдýѧÕßÃǵĽøÒ»²½·¢Ã÷¡£¡ £¡£¡£ÖйúÉúÎïÖÆÒ©³ÖÐøͶÈëÁ¢ÒìÑз¢ £¬ £¬½«Îª¸ÄÉÆθ°©»¼ÕßÉúÑÄÂÊÌṩ¸ü¶à·½°¸¡£¡ £¡£¡£
²Î¿¼ÎÄÏ×£º
[1]BRAY F.LAVERSANNE M. SUNG H, et al. Global cancer statisties 2022:GL0B0CAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].CA Cancer J Clin, 2024,74(3): 229-263.
[2]HAN B F, ZHENG R S, ZENG H M, et al. Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent, 2024,4(1): 47-53.
[3]Wang J, Du L, Chen X. Adenosine signaling: Optimal target for gastric cancer immunotherapy. Front Immunol. 2022 Sep 16;13:1027838.
[4]Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020 Aug 29;396(10251):635-648.
[5]ÖйúÁÙ´²Ö×Áöѧ»áÖ¸ÄÏÊÂÇéίԱ»á.¡¶ÖйúÁÙ´²Ö×Áöѧ»á£¨CSCO£©Î¸°©ÕïÁÆÖ¸ÄÏ2024¡·. ÈËÃñÎÀÉú³öÊéÉç. ±±¾©. 2024.
[6]ãÆÎÄÃ÷ £¬ £¬±¦Ó¨ÄÈ £¬ £¬ÓôÖ¾Áú £¬ £¬µÈ.ICAM-1ºÍVEGFÔÚ¹¬¾±°©×éÖ¯Öеıí´ïÓë·ÅÁÆÃô¸ÐÏà¹ØÐÔÑо¿[J].ÄÚÃɹÅÒ½¿Æ´óѧѧ±¨ £¬ £¬2017£»£»£»39£¨6£©£º539-541.
[7]SAITO H,FUKUHARA T, FURUYA N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-celllung cancer(NEJ026):interim analysis of an open-label,randomised,multicentre,phase 3 trial[J].Lancet Oncol,2019,20(5):625-635.
[8]Klempner SJ, Janjigian YY, Wainberg ZA, et al. Examining biomarker overlap and outcomes in Claudin18.2-positive gastroesophageal adenocarcinomas[J]. ESM0 Open, 2023 ,8(2):100778.
[9]Wainberg ZA, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet Oncology £¬ £¬2022, 23(11):1430-1440.
¡ø ÉÏÏ»¬¶¯Éó²é¸ü¶à
ÉùÃ÷£º
1.ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷ £¬ £¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ £¬ £¬·Ç¹ã¸æÓÃ;¡£¡ £¡£¡£
2.±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£¡ £¡£¡£
3.±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼ £¬ £¬²»¿ÉÒÔÈκη½Ê½È¡´úרҵµÄÒ½ÁÆÖ¸µ¼ £¬ £¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£¡ £¡£¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢ £¬ £¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£¡ £¡£¡£
Ç°Õ°ÐÔÉùÃ÷£º
±¾ÐÂΟåÖаüÀ¨Èô¸ÉÇ°Õ°ÐÔ³ÂÊö £¬ £¬°üÀ¨Óйء¾×¢ÉäÓÃÇúÍ×Öéµ¥¿¹£¨É̱êÃû£ºÈüÍ×£©¡¢¡¢¡¢±´·¥Öéµ¥¿¹×¢ÉäÒº£¨É̱êÃû£º°²±¶Ë¹£©¡¢¡¢¡¢TQB2103¡¢¡¢¡¢TQB2210¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢¡¢¡¢ÁÙ´²»ñÒæÓëÓÅÊƵÄÔ¤ÆÚ¡¢¡¢¡¢ÉÌÒµ»¯Õ¹Íû¡¢¡¢¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ £¬ £¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£¡ £¡£¡£“Ô¤ÆÚ”¡¢¡¢¡¢“ÏàÐÅ”¡¢¡¢¡¢“¼ÌÐø”¡¢¡¢¡¢“¿ÉÄÜ”¡¢¡¢¡¢“Ô¤¼Æ”¡¢¡¢¡¢“ÆÚÍû”¡¢¡¢¡¢“ÓÐÍû”¡¢¡¢¡¢“ÍýÏ딡¢¡¢¡¢“ÍýÏ딡¢¡¢¡¢“DZÔÚ”¡¢¡¢¡¢“Ô¤²â”¡¢¡¢¡¢“Ô¤¼Æ”¡¢¡¢¡¢“Ó¦¸Ã”¡¢¡¢¡¢“½«”¡¢¡¢¡¢“Ä┡¢¡¢¡¢“»á”ºÍÀàËƱí´ïÖ¼ÔÚʶ±ðÇ°Õ°ÐÔ³ÂÊö £¬ £¬µ«²¢·ÇËùÓÐÇ°Õ°ÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£¡ £¡£¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÔ¤²â»òÆÚÍû £¬ £¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢¡¢¡¢Ñз¢¡¢¡¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»ò·çÏÕµÄÓ°Ïì £¬ £¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëÇ°Õ°ÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£¡ £¡£¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄ·çÏÕ £¬ £¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄÇ°Õ°ÐÔ³ÂÊö £¬ £¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£¡ £¡£¡£³ý·ÇÖ´·¨ÒªÇó £¬ £¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢¡¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎÇ°Õ°ÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£¡ £¡£¡£